GlassScriptPhysician profile
Katie Callene Masters
NPI 1659822930
$4,993.38
in general payments reported to CMS, 2019-2025
41 companies · $670 in 2025
The $670 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $924 · 2022: $1,061 · 2023: $1,110 · 2024: $1,228 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.41 | 2021-2025 | |
| Novo Nordisk INC | $853.48 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $632.09 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $306.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $185.29 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Lilly USA, LLC | $184.73 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $162.17 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $152.39 | 2023-2025 | Veozah |
| Amgen INC. | $148.80 | 2021-2025 | Otezla, Repatha, Otezla |
| Bausch Health US, LLC | $138.34 | 2021-2023 | Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $133.66 | 2022 | |
| Glaxosmithkline, LLC. | $109.52 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Philips North America LLC | $76.58 | 2022-2024 | (Ck7) Extended Holter |
| Takeda Pharmaceuticals U.S.A., INC. | $75.35 | 2021-2022 | |
| Sanofi Pasteur INC. | $74.27 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $66.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $66.08 | 2021 | |
| Edwards Lifesciences Corporation | $51.21 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $49.44 | 2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.79 | 2022-2023 | Xifaxan |
| Eisai INC. | $40.36 | 2021 | |
| Exeltis, USA INC. | $38.61 | 2024-2025 | Slynd |
| Nevro Corp. | $38.35 | 2022-2023 | Senza |
| Amarin Pharma, INC. | $35.01 | 2021 | |
| Seqirus USA INC | $29.20 | 2024 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $27.36 | 2022-2023 | Quviviq |
| Ibsa Pharma INC. | $24.08 | 2025 | Tirosint, Flector, Licart |
| Hologic Sales and Service, LLC | $23.70 | 2025 | Aptima, Thinprep 2000 Processor |
| Inspire Medical Systems, INC. | $22.39 | 2023 | Inspire |
| Ethicon US, LLC | $22.29 | 2022 | |
| Phadia US INC. | $21.70 | 2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $20.46 | 2021 | |
| Genentech USA, INC. | $19.40 | 2021 | |
| Impel Pharmaceuticals INC. | $18.65 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.44 | 2023 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $15.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.43 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.13 | 2023 | Unithroid |
| Lucid Diagnostics INC. | $14.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.58 | 2021 | |
| Medtronic, INC. | $13.87 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.